Trial · NCT07886879
Parkinson's Disease in Type 1 Gaucher Disease
NCT07886879, Recruiting, Icahn School of Medicine at Mount Sinai
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Parkinson's Disease in Type 1 Gaucher Disease. Trials, record NCT07886879. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07886879
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Parkinson's Disease in Type 1 Gaucher Disease
- NCT number
- NCT07886879
- Status
- Recruiting
- Enrollment
- 100 participants, estimated
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Conditions
- Parkinson Disease (PD), Type 1 Gaucher Disease
- First posted
- 2026-10-21
- Last updated
- 2026-11-05
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Parts I, II, and IV | Day 1 | The MDS-UPDRS is a standardized clinical assessment used by neurologists to study PD. Three parts (I/II/IV) are used to evaluate individuals' symptoms of Parkinson's Disease, including non-motor and motor experiences of daily living and common PD comorbidities. Each part contains several items (each rated by severity on a 0 to 4 scale) Part I (subscale from 0-52), Part II (subscale from 0-52), and Part IV (subscale from 0-24) are summed for a total score from 0-128. A higher score indicates higher severity of PD-related symptoms. |
| Primary | REM Behavioral Disorder Screening Questionnaire (RBDSQ) | Day 1 | RBDSQ is a simple 10-item yes/no response screening questionnaire to screen for REM sleep behavior disorders, a known risk factor for PD. The range for this scale is 0 to 13 points. Each item contributes 1 point except a single item that contributes 4 points for up to four specific manifestations of REM Behavior Disorders. A score of 5 or higher indicates a positive screening threshold for REM Behavioral Disorder (RBD). |
| Primary | Montreal Cognitive Assessment (MoCA) | Day 1 | MoCA is a 10-minute cognitive screening tool used to detect mild-cognitive impairment (MCI) by assessing short-term memory, visuospatial abilities, executive functions, attention and concentration, working memory, language, and orientation to time and place. The scale ranges from 0 to 30 points. Severe impairment scores between 0-9 and normal cognitive performance scored at 26 and above. The higher the score, the less cognitive impairment. |
| Primary | Scales for Outcomes in Parkinson's Disease - Autonomic Dysfunction (SCOPA-AUT) | Day 1 | SCOPA-AUT is a 25-item questionnaire used to assess autonomic symptoms (gastrointestinal, urinary, cardiovascular, thermoregulatory, pupillomotor, sexual) in patients with Parkinson's disease. This scale includes subscales for gastrointestinal (0-7), urinary (0-6), cardiovascular (0-3), thermoregulatory (0-4), pupillomotor (0-1), and sexual (2 items for men and 2 items for women) symptoms. Total scale ranges from 0-23 where a higher score in any or total symptoms indicates higher severity. |
| Primary | University of Pennsylvania Smell Identification Test (UPSIT) | Day 1 | UPSIT is a reliable 40-item test of olfactory function using microencapsulated odorants which are released by scratching scent strips across four small booklets. The individual then picks the answer from a list of four multiple-choice options. The final score is the number of correct answers between 0 and 40. A lower score indicates olfactory dysfunction, and a higher score indicates a more normal sense of smell. |
| Primary | Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III | Day 1 | This section includes 18 items assessing tone, tremor, gait, movement, and posture at various sites of the body which are all rated on a scale of 0 to 4, with 4 indicating more severe symptoms. It also includes four yes/no questions regarding current medication / treatment for ongoing dyskinesia during the examination as well as a single 0 to 5 rating on overall functional status, with higher ratings reflecting greater functional impairment. The score ranges from 0-133 with higher score indicating more severe impairment. |
| Secondary | Number of individuals with movement disorder other than Parkinson's Disease | Day 1 | The number of individuals that have another movement disorder on this examination not covered by the UPDRS III. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07886879
GET https://conductscience.org/api/trials/v1/NCT07886879/registered